A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

The requested reference [d7fac657387abba5a39700c739136277d33904f3] no longer exists in our database. It has been replaced by the current reference: [5095d2b9a9f7141a2d10b644142ce70dca0e5290]

Authors Shandong University -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Links ClinicalTrials.gov
Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong University and other 4 well-known hospitals in China. In order to report the efficacy and safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose dexamethasone therapy.
Epistemonikos ID: 35822ad5a8f3584f1c45c2b74c3fae310498d04a
First added on: May 11, 2024